http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
-
Anavex Life Sciences (AVXL) Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
-
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
-
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
-
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
-
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
-
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
-
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
-
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
-
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
-
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
-
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
-
Anavex Life Sciences (AVXL) Reports Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX3-71
-
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
-
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
-
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
-
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
-
Anavex Life Sciences (AVXL): Results from Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
-
Anavex Life Sciences (AVXL) announces addition and appointment of new senior team members
-
Anavex Life Sciences Announces Expansion of Leadership Team
-
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
-
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
-
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
-
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
-
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
-
Anavex Life Sciences (AVXL) Reports Publication Confirming Pharmacokinetic Dose Proportionality of ANAVEX3-71 in Humans
-
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
-
Anavex Life Sciences (AVXL) Announces Phase 2 Trial of ANAVEX3-71 in Schizophrenia
-
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
-
Anavex Life Sciences (AVXL) Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Neurodevelopmental Disorders
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
-
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Anavex Life Sciences (AVXL) Provides an Update on Rett Syndrome Program
-
Anavex Life Sciences Provides an Update on Rett Syndrome Program
-
Anavex Life Sciences (AVXL) Announces First Entire Clinical Gene Pathway Data of ANAVEX2-73 from AVATAR Study in Patients with Rett Syndrome
-
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
-
Anavex Life Sciences (AVXL) Received Agreement from the CHMP for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
-
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
-
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
-
Anavex Life Sciences (AVXL) Announces Grant of U.S. Patent for Blarcamesine
